Adipocytic progenitor cells give rise to pathogenic myofibroblasts: adipocyte-to-mesenchymal transition and its emerging role in fibrosis in multiple organs
Current rheumatology reports, 2020•Springer
Abstract Purpose of Review Adipocytes have recently been shown to be able to reprogram
to a myofibroblastic phenotype in a process termed adipocyte mesenchymal transition
(AMT). This review seeks to discuss the relevance of this process to disease and explore its
mechanisms. Recent Findings AMT occurs in multiple organs and diseases,
transdifferentiation goes through a precursor cell and there is a reversible process that can
be influenced by metabolic stress, myeloid cells, immune dysregulation, and …
to a myofibroblastic phenotype in a process termed adipocyte mesenchymal transition
(AMT). This review seeks to discuss the relevance of this process to disease and explore its
mechanisms. Recent Findings AMT occurs in multiple organs and diseases,
transdifferentiation goes through a precursor cell and there is a reversible process that can
be influenced by metabolic stress, myeloid cells, immune dysregulation, and …
Purpose of Review
Adipocytes have recently been shown to be able to reprogram to a myofibroblastic phenotype in a process termed adipocyte mesenchymal transition (AMT). This review seeks to discuss the relevance of this process to disease and explore its mechanisms.
Recent Findings
AMT occurs in multiple organs and diseases, transdifferentiation goes through a precursor cell and there is a reversible process that can be influenced by metabolic stress, myeloid cells, immune dysregulation, and pharmacological intervention.
Summary
AMT is a newly appreciated and highly relevant process in multiple forms of fibrosis. Targeting AMT may serve as a novel method of treating fibrosis.
Springer
